Back to Search Start Over

Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma

Authors :
John Lister
Santhosh Sadashiv
Rodney E. Wegner
Veli Bakalov
Thejus T. Jayakrishnan
Zena Chahine
Source :
Hematology/Oncology and Stem Cell Therapy, Vol 14, Iss 3, Pp 218-230 (2021), Hematology/Oncology and Stem Cell Therapy
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Background: Disparities driven by socioeconomic factors have been shown to impact outcomes for cancer patients. We sought to explore this relationship among patients with multiple myeloma (MM) who were not considered for hematopoietic stem cell transplant in the first-line setting and how it varied over time. Methods: We queried the National Cancer Database for patients diagnosed with MM between 2004 and 2016 and included only those who received systemic therapy as the first-line treatment. Enrollment rates for therapy were calculated as receipt of systemic therapy as the incident event of interest (numerator) over time to initiation of therapy (denominator) and used to calculate incident rate ratios that were further analyzed using Poisson regression analysis. A multivariate Cox proportional hazards model was constructed for survival analysis, and differences were reported as hazard ratios (HRs). Results: We identified 56,102 patients for enrollment analysis and 50,543 patients for survival analysis. Therapy enrollment in a multivariate model was significantly impacted by race and sex (p 1), whereas female sex, non-Hispanic black race, higher income, and treatment at an academic center were associated with improved survival (HR

Details

Language :
English
ISSN :
16583876
Volume :
14
Issue :
3
Database :
OpenAIRE
Journal :
Hematology/Oncology and Stem Cell Therapy
Accession number :
edsair.doi.dedup.....92c7951bf3bf8b35daa46f1682f91e13